Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078436 | SCV000110289 | uncertain significance | not provided | 2013-03-18 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000146479 | SCV000193768 | pathogenic | Severe X-linked myotubular myopathy | 2013-02-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000146479 | SCV001448361 | likely pathogenic | Severe X-linked myotubular myopathy | 2020-11-02 | criteria provided, single submitter | clinical testing | Variant summary: MTM1 c.688T>C (p.Trp230Arg) results in a non-conservative amino acid change located in the Myotubularin-like phosphatase domain (IPR010569) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 182821 control chromosomes (gnomAD). p.Trp230Arg has been reported in the literature in individuals affected with Severe X-Linked Myotubular Myopathy following testing via sequencing technologies (e.g. Tsai_2005, Nishikawa_2019). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |